Sachdeva A, Hung YY, Solomon MD, et al. - Given that there is a lack of knowledge regarding the optimal duration of dual antiplatelet therapy (DAPT) following treatment of chronic total occlusions (CTO) with percutaneous coronary intervention (PCI), researchers investigated whether extended (> 12 months) DAPT was related to a net clinical advantage. Patients who had successful CTO PCI within Kaiser Permanente Northern California between 2009 and 2016 were included in this study. Patients on DAPT ≤ vs > 12 months were compared in terms of baseline demographic, clinical, as well as procedural features. Findings revealed that lower mortality or myocardial infarction without an increase in bleeding was achieved with > 12 months of DAPT. To assess the optimal duration of DAPT in this unique subgroup, prospective investigations are required.